Pet owners have always wished that their four-legged friends could talk and let them know they are sick or hurting. Emerging technology could soon make their wish come true.

Yesterday, a federal court in Wisconsin granted Eli Lilly and Company and Elanco US Inc.’s motion for a nationwide preliminary injunction against international dairy conglomerate Arla Foods and its “Live Unprocessed” ad campaign, which makes false and misleading claims about recombinant bovine somatotropin (rbST), a proven and safe dairy technology approved by the FDA in 1993.

Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), today released its inaugural global Corporate Social Responsibility (CSR) Impact Report demonstrating its commitment to impact food security and the support of the human-animal bond.

GREENFIELD, Ind., May 24, 2017 –Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), today announced that it received a grant from the Bill & Melinda Gates Foundation to provide sustainable development solutions to address food insecurity in East African countries. The commitment will work to improve animal health and productivity in dairy herds and poultry flocks for smallholder farms in Kenya, Uganda and Tanzania.

Last Friday, Eli Lilly Elanco US Inc. (Elanco) initiated a legal action in the U.S. District Court for the Eastern District of Wisconsin against international dairy conglomerate Arla Foods demanding that Arla immediately cease its false advertising campaign and unfair business practices against rbST, a proven and safe dairy technology approved by the FDA in 1993. Recombinant bovine somatotropin (rbST) is a supplement marketed and sold by Elanco under the brand name Posilac^®.

The animal health industry believes it’s our responsibility to help farmers produce enough safe, affordable food in a sustainable manner while safeguarding animal health, welfare and food safety. We also have a responsibility to help keep animals healthy, and to treat sick animals while balancing the long-term effectiveness of antibiotics for animal and human use.

Representatives from Elanco Animal Health will be on hand to officially open the doors to its new autogenous poultry vaccine facility in Winslow, Maine, on Wednesday, May 3, 2017 at 1:30 p.m. EST.

The first of its kind for Elanco, the new state-of-the-art facility is dedicated solely on manufacturing customized, high-quality inactivated vaccines for the poultry industry that will assist in the prevention of unique disease challenges and protection from food safety issues that can’t be addressed with commercially available vaccines.

Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), in collaboration with Purdue University’s College of Veterinary Medicine, today released preliminary research findings that support the power of the human-animal bond. 

Jaguar Animal Health, Inc. (NASDAQ: JAGX) and Elanco US Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), today announced an agreement (the “Agreement”) to license, develop, and commercialize Canalevia^™, a Jaguar drug product candidate under investigation for treatment of acute and chemotherapy-induced diarrhea (“CID”) in dogs.

Veterinarians have a new targeted tool for the management of pain and inflammation associated with canine osteoarthritis (OA). Elanco Animal Health announced that Galliprant^® (grapiprant tablets), a first-in-class piprant, is now available to veterinarians for once-daily use in dogs with OA. Galliprant can be used in patients as young as 9 months, weighing 8 pounds or more, and most dogs can be dosed once a day with a whole or half tablet.

Elanco Animal Health, a division of Eli Lilly and Company, has launched Itrafungol™ (itraconazole oral solution), the only marketed FDA-approved* systemic treatment for dermatophytosis (ringworm) caused by Microsporum canis in cats.

Today Elanco US Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), announced that it has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc’s (BIVI) U.S. feline, canine and rabies vaccines portfolio – as well as a fully integrated manufacturing and R&D site and several pipeline assets.

Elanco Animal Health announces the FDA approval of Onsior Tablets for Dogs and Onsior injection for the treatment of postoperative pain and inflammation associated with soft- tissue surgery in dogs aged 4 months or older and weighing 5.5 pounds (2.5 kg) or more. Veterinarians can now use the same nonsteroidal anti-inflammatory (NSAID) to manage surgical pain in both dogs and cats.

Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), announces support of Pet Partners’ efforts to build on its therapy animal program and help facilitate international expansion. Pet Partners is a non-profit human services organization dedicated to improving human health and well-being through the human animal bond. The initiatives are being funded by a $100,000 grant through Elanco from the Lilly Foundation.

Elanco’s novel in-feed treatment has been approved for the prevention and control of sea lice in salmon and trout in Chile. Sea lice are a significant challenge for salmon farmers, and this new breakthrough tool offers an innovative, long-acting treatment alternative. Chile is the first country to grant marketing authorization to the treatment.

Today HATCH™ for Hunger donates 293,760 eggs to 17 different food banks across the Midwest to help nourish the food insecure. HATCH and Kroger also announced today that all donations made at the Kroger checkout, online or text to donate from now through the end of 2016 Kroger will match. You can make a donation or learn how by visiting www.hatchforhunger.com or texting HATCH to 52000.

Elanco Animal Health has been a proud sponsor of the National FFA for the past 36 years. Building leaders in agriculture as well as fighting food insecurity and hunger have been common connection points for the two organizations and are the pillars of their partnership.

Elanco is expanding our U.S. companion animal portfolio by acquiring an innovative platform of companion animal vaccines with high brand awareness and an established, loyal customer base of veterinarians.

More than 250 global food and health leaders representing the public and private sector gathered in Washington, D.C. this week at the One Health Summit, and declared priorities to help combat antimicrobial resistance as part of efforts to produce a sustainable food supply.

Aggressive eight-point plan to help safeguard animal and human health makes progress, creates pipeline of alternatives to shared-class antibiotics

Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and the makers of Trifexis® (spinosad + milbemycin oxime), today launched its Celebrate the Bond video series that lets viewers share the experience of two individuals embarking on life-changing relationships.

Elanco Animal Health announced today that the U.S. Department of Agriculture (USDA) has approved AviPro^® Megan^® Egg for Salmonella prevention in live turkey production. AviPro Megan Egg for turkeys is a USDA-licensed vaccine recommended as an aid in the prevention of Salmonella Typhimurium (ST) colonization of the liver and spleen.

Findings from a five-year, 54-nation study of broiler enteric health trends, including how improvements in broiler enteric health may impact the health of poultry producers’ businesses, will be shared during the Poultry Science Association (PSA) Annual Meeting in New Orleans, on Tuesday, July 12. The presentation will highlight key findings from the study which identified the most common enteric health issues facing the broiler industry across time and geographic regions.

Elanco Canada has recently received approval from Health Canada for expanded respiratory disease treatment coverage for Pulmotil® AC.

Last June leaders from across human and animal health gathered at the White House Forum on Antibiotic Stewardship to improve antibiotic stewardship and to protect long-term effectiveness of antibiotics. Building on the collaboration created at that event, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), has announced a One Health Antibiotic Stewardship Summit for global industry and food chain leaders to continue building dialogue and actions that address this challenge.

GREENFIELD, Ind. June 23, 2016 — Elanco Animal Health has launched Agita® 10 WG, a first-choice insecticide for fly and beetle control for animal housing in the U.S. Agita 10 WG features a unique, potent active ingredient that delivers a quick kill and long-lasting residual. Reducing pests reduces their impact on animal well-being and performance potential.

Today Elanco Animal Health, a division of Eli Lilly and Company, (NYSE: LLY) and EnBiotix, Inc., announced a collaboration to explore the application of EnBiotix’s engineered phage technology in specific animal health targets. If successful, this endeavor could result in potential alternatives for traditional antibiotics in animals.

Today Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), announces the opening of a state-of-the-art Vaccines Innovation Center whose intentional design will enable scientists to address some of animal health’s most pressing issues.

Elanco Animal Health and United Way Worldwide announce a strategic partnership to address global hunger/food security. Elanco is committing $300,000 to “Break the Cycle of Hunger” in 100 Communities by 2020.

GREENFIELD, Ind. May 19, 2016 — Elanco Animal Health introduces Inteprity^TM, a first-in-class, animal-use only, in-feed antibiotic developed for the prevention of mortality caused by necrotic enteritis associated with Clostridium perfringens in broiler chickens. Under supervision of a veterinarian, Inteprity supports bird health and well-being, and demonstrates a responsible approach to antibiotic use.

The constant threat of bacterial enteritis in poultry flocks is serious, and a new survey by Elanco Animal Health reveals important trends related to bacterial enteritis, including prevalence, producer attitudes and best management practices.

Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced that Elanco has licensed animal health rights to Aratana’s Galliprant (grapiprant tablets), an FDA-approved therapeutic for the control of pain and inflammation associated with osteoarthritis in dogs. The agreement grants Elanco exclusive rights to develop, manufacture, market, and commercialize Galliprant globally, and co-promote the product with Aratana in the United States.

Elanco Animal Health, in collaboration with the American Association of Avian Pathologists Foundation (AAAP), is pleased to announce the establishment of two scholarships available to students pursuing degrees in poultry science and veterinary medicine at an accredited college or university.

Surmax® 200, a new swine product from Elanco Animal Health, represents a first-in-class, animal-use only antibiotic for reduction in the incidence and severity of diarrhea in the presence of pathogenic Escherichia coli in groups of weaned pigs. Surmax® 200 is an orthosomycin antibiotic, a new class of antibiotics now on the market for animal use only.

Today, Elanco Animal Health, a division of Eli Lilly and Company
(NYSE: LLY), announced the approval of Imrestor™ (pegbovigrastim injection) – the first product of its
kind for the dairy industry.

Available only by veterinary prescription, Imrestor is now FDA approved for the reduction in the
incidence of clinical mastitis in the first 30 days of lactation in periparturient dairy cows and
periparturient replacement dairy heifers. Imrestor is a protein that helps support the natural function of
a dairy cow’s immune system during the critical time around calving, when she is most vulnerable
to mastitis.

Independent research conducted by Novometrix Inc. has verified that the Intestinal Integrity (I2) Index used to measure gut health and function in broilers, correlates closely with live performance outcomes such as daily weight gain and feed efficiency in broiler flocks around the globe. The research findings were presented during the International Processing & Production Expo’s (IPPE) Tech Xchange on Wednesday, January 27, in Atlanta, GA (USA).

Regional results of a new survey show U.S. dairy producers are acutely aware of the consequences of immune suppression, and 59 percent of survey respondents rate mastitis as the top complication of compromised immunity.  “As we reframe how we manage the vulnerable time around calving and make immune suppression a priority, we know that more than 80 percent of U.S. producers are looking to their veterinarians for help in protecting their cows’ immune systems,” said Paul Rapnicki, DVM, MBA, Dairy Technical Consultant, Elanco Animal Health. “Focusing on immune suppression as the cause rather than managing the consequences will decrease costly diseases post-calving, while setting cows up for a productive lactation.”

Elanco outlined to beef producers at the Cattle Industry Convention information to better understand and prepare to implement Veterinary Feed Directive (VFD) regulations. The U.S. Food and Drug Administration’s (FDA’s) new VFD rule for managing antibiotic use in livestock will go into effect Jan. 1, 2017, which means now is the time for producers to update their herd-health plans. Elanco has developed informational resources about the VFD, and suggests four steps farmers and ranchers can take to meet this deadline.

Elanco Animal Health has made the business decision to exit ownership of our Dundee manufacturing operations. Over the coming months, one of our top priorities will be to seek a buyer for ongoing manufacturing operations at the site. The site will operate as normal during this time – continuing to deliver a safe, high-quality, reliable supply to customers. If efforts to find a suitable buyer are unsuccessful, we will commence the transfer of product supply to other manufacturing sites, leading to a site closure. If this were to occur, the company anticipates the transition of production would take approximately two years to complete.

The difficult decision to close our Sligo, Ireland manufacturing facility was reached as part of an in-depth evaluation of our global manufacturing operations. These business decisions were made after evaluating operations across Elanco’s global manufacturing network, and are not a reflection of site performance at Sligo. The changes, while difficult, are aligned with Elanco’s objectives to maintain a competitive advantage in the continually changing animal health business.

Kavault®, a new swine product from Elanco Animal Health, represents a first-in-class, animal use-only antibiotic for reduction in incidence and overall severity of diarrhea in the presence of pathogenic Escherichia coli in groups of weaned pigs. Kavault is an orthosomycin antibiotic, which is a new class of antibiotics in the US market for animal use only (not medically important)*. Administered under a veterinary feed directive (VFD), Kavault is a solution for pigs up to 14 weeks of age.

Today Elanco Animal Health released an updated report  in support of its groundbreaking food security movement, “ENOUGH: Building a Food-Secure Tomorrow”. The report and its new, interactive website can be found at ENOUGHMovement.com.  The ENOUGH report is anchored in true sustainability and focuses on four key pillars: Innovation, Choice, Access, and Nutrition. Each pillar offers a modern approach to tackling the global issue of food insecurity.

Today Elanco Animal Health announced the launch of OSURNIA, a treatment for canine otitis externa. An estimated one in 5 dogs will experience the discomfort of otitis externa – an inflammation of the ear canal that is often accompanied by ear pain, itchy ears, a strong odor and muffled hearing. Otitis externa is the second most common canine veterinary diagnosis in the U.S. and owner compliance is the biggest issue veterinarians face when treating these affected dogs.

After providing 100,039 eggs to more than 8,000 families in Indiana during a 10-week pilot program, HATCH™ announced it will extend its program with The Kroger Co. (NYSE: KR) and Rose Acre Farms through 2015.

President Jeff Simmons participates in White House Forum on Antibiotic Stewardship; outlines company’s aggressive eight-step plan to help safeguard animal and human health and deliver 10 new alternatives to the most challenging diseases.

In the first four weeks since HATCH™ — a new way consumers, food stores and farmers can work together to provide eggs to undernourished people — was announced, 5,250 families in Central Indiana have received a dozen eggs through this unique program. This means more than 63,000 eggs have helped people of all ages fight undernourishment through the power of egg protein. The pilot program continues through June 20, with HATCH providing one egg to a local food bank for each dozen Kroger-brand medium eggs purchased.

Today, Elanco, The Kroger Co.’s Central Division (NYSE: KR), Rose Acre Farms, Gleaners Food Bank and Midwest Food Bank introduced a way consumers, food stores and farmers can easily work together to provide eggs to undernourished people of all ages. Called HATCHTM, this innovative community partnership was celebrated by community leaders, government officials, association representatives and food shoppers during a special event at a Kroger store in Indianapolis. The first HATCH pilot project, which involves 66 Central Indiana Kroger stores, will provide one egg to a local food bank for each dozen Kroger-brand medium eggs purchased through June 20.

A new survey commissioned by Elanco’s ENOUGH Movement and conducted by SWG on 2,000 people across Italy, Germany, France and UK, shows that – based on their own general perception on food habits and behaviours as well as of their countrymen – about 50% of the interviewees say they cannot follow a sufficiently varied nutritional diet. In particular, fish, beef and pork are among foods often absent from people’s diet.

Elanco announced results of its #Feedthe9 community outreach to help fight hunger. In support of its vision for a food-secure world, Elanco’s poultry business unit donated a total of $18,000 to three customers’ community partners, and worked with 400 employees at GNP Company^TM and Tyson Foods locations in three states to provide more than 10 tons of food and package over 14,000 meals.

With continued improvement for farming practices, such as better year-round nutrition and improved breeding and genetic selection, fewer than 1.7 billion cattle and water buffalo will be needed to provide adequate global beef supplies. This is nearly the same size as today’s global herd of cattle and water buffalo, which is approximately 1.68 billion. More importantly, the beef industry can freeze its environmental footprint to 2010 levels.

Elanco announced that it has completed the acquisition of Novartis Animal Health, which will further position Lilly’s Elanco as a global leader in the animal health industry.

3-year project to develop new enzyme combinations for Canadian pork and poultry producers

Institute will share technical know how to enable farmers to sustainably meet China's fast-growing demand for milk.

Elanco Animal Health and Tyson Foods host benefit Dare to Care food banks.  Volunteers donate food and learn about food security at #Feedthe9TysonIN

Elanco Animal Health and Tyson Foods host event to benefit Operation Reach Out.  Volunteers donate food and learn about food security at #Feedthe9Tyson/NC

Elanco Animal Health and Dow AgroSciences Announce Strategic R&D Agreement
Agreement will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.  

Elanco Animal Health and Dow AgroSciences Announce Strategic R&D Agreement
Agreement will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population.  

Elanco celebrates World Hunger Day with a new project with Heifer International designed to create sustainable livelihoods for 1M.

Elanco announces an agreement to acquire Novartis Animal Health, creating a global leader in animal health innovation and customer value. The $5.4 billion deal creates world’s second-largest animal health company.

Elanco announces an agreement to acquire Lohmann Animal Health, a privately-held company headquartered in Cuxhaven, Germany. The acquisition will establish Elanco as a global poultry leader, extending our presence into layers and expanding our growing vaccine presence.

• Innovation, Choice and Trade - the Three Pillars for Ensuring a Food Secure World before 2050

• The report, written by Elanco President Jeff Simmons, advocates for farmer access to innovative tools in order to feed a growing global population and save natural resources.

• Elanco conducted the second edition (2013) of the International Consumer Attitudes Study to determine the key issues for consumers when buying food. Based on two key criteria – 1) unaided questions and 2) consumer spending data, the research includes 34 studies from 26 countries accounting for more than 100,000 consumers.  

• For more information, visit www.SensibleTable.com.  Join @JeffSimmons2050 and @Elanco for more discussion on Twitter with #FeedThe9.  The website calls for advocates to join The Enough Movement and provides resources for campaigners to help make their voices heard in the fight for a food secure tomorrow.

• China investment reinforces Elanco's commitment to China's efforts to ensure food safety and enhance food security and rural income.
• Elanco is a global leader in providing innovative solutions to enhance safe, affordable, abundant food production.
• Minority equity stake in China Animal Healthcare is valued at approximately $100 million USD.

Comfortis^® (spinosad), the month-long flavored tablet that has been protecting dogs from fleas since 2007 has now been approved for use in cats and smaller dogs. As a result of the recent FDA approval, Comfortis can now be used in cats and kittens greater than 2 lbs and 14 weeks and older. In addition, our new 90 mg tablet will allow veterinarians to prescribe Comfortis for smaller dogs 3.3-4.9 lbs and 14 weeks and older.

The Codex Alimentarius Commission has adopted global food safety standards for ractopamine hydrochloride (ractopamine) at its 35th Session in Rome.

During a panel discussion with senior global leaders at the Chicago Council on Global Affairs Symposium “Advancing Food and Nutrition Security at the G8 Summit” in Washington, Jeff Simmons urged leaders to take action now to address the challenge of developing more efficient food production systems and pressed for policy alternatives that provide long-term, sustainable solutions to hunger, food inflation and food availability.

Hygromix, an in-feed medication for control of parasite infections in chickens, will once again be available in the United States starting mid-April. Hygromix is the only FDA-approved poultry product that controls all three nematodes; capillary worms (Capillaria obsignata), cecal worms (Heterakis gallinae) and large roundworms (Ascaris galli), and is recommended for pullets and breeders.

Elanco announces an agreement to acquire ChemGen, a privately-held enzyme company with 25 years of experience in the market place, continuing Elanco’s commitment to provide customers with leading animal productivity solutions. Enzymes have become increasingly important in helping the animal better achieve its natural potential, while getting the most out of the natural resources used in production.

Elanco Companion Animal Health has launched Trifexis^®, (spinosad + milbemycin oxime), a broad spectrum parasiticide that kills fleas and is indicated for the prevention and treatment of flea infestations, the prevention of heartworm disease, and the treatment and control of adult hookworm, roundworm and whipworm infections in dogs and puppies 8 weeks and older.

Poultry producers have a new tool to help rid birds of a costly health threat. Elector^® PSP has received regulatory approval for the control of northern fowl mites (Ornithonyssus sylviarum), the most common external poultry parasite in the United States.

Indiana’s record-setting conservation program took another step forward today with the introduction of a unique project that will showcase the compatibility of conservation and farming, and protect more than 300 acres at Lilly's Elanco manufacturing facility in Clinton.

Poultry producers have a new tool to help rid birds of a costly health threat. Elector^® PSP has received regulatory approval for the control of northern fowl mites (Ornithonyssus sylviarum), the most common external poultry parasite in the United States.

Elanco Companion Animal Health has launched Trifexis^®, (spinosad + milbemycin oxime), a broad spectrum parasiticide that kills fleas and is indicated for the prevention and treatment of flea infestations, the prevention of heartworm disease, and the treatment and control of adult hookworm, roundworm and whipworm infections in dogs and puppies 8 weeks and older.

Elanco Companion Animal Health has brought to market another veterinary product innovation with the launch of Assurity^™, a topical flea treatment developed just for cats. Assurity kills 98 percent to 100 percent of fleas within 12 hours, killing the fleas before they can lay eggs. It is 100 percent effective for a full month.

Elanco announces the addition of Keto-Test^® to its current portfolio of productivity products for dairy producers. Keto-Test is a color-changing test strip that indicates the presence of ketones in the milk of dairy cows. Though commercially available in other countries, this is the first U.S. introduction of the product.

Elanco, the animal health division of Eli Lilly and Company, has announced that Lilly has signed an agreement to acquire the European rights to a portfolio of certain Pfizer Animal Health products. The products, including vaccines, parasiticides and feed additives, are used in both the production animal and companion animal markets.

Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), will celebrate its 10th year of giving back to local communities around the world during Global Day of Service on Thursday, Sept. 28. Day of Service is one of the largest single-day corporate volunteer programs in the world.

Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), announced today a strategic shift in its dairy portfolio. The company will optimize investment to focus on future dairy innovations that address the most challenging issues and diseases farmers face in their herds today. Concurrently, Elanco is exploring strategic options for rbST, including seeking a buyer for the molecule and its Augusta, Ga., manufacturing facility.

LEAWOOD, Kan. (U.S.) (For EU audience), November 10, 2017 — Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Medicine Agency’s (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion to recommend the marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union. Following the positive opinion, the European Commission will complete the regulatory process for a final decision on the Marketing Authorisation in early 2018.

Greenfield, Ind. (Jan. 11, 2018) – Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), named Sarena Lin as senior vice president, North America Operations and Global Strategy, joining Elanco’s Leadership Team and reporting to Elanco president, Jeffrey Simmons.

LEAWOOD, Kan. (U.S.) (For EU audience), January 11, 2018 — Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Commission adopted the decision to grant marketing authorization of GALLIPRANT® (grapiprant tablets) in the European Union.

Greenfield, Ind. (JANUARY, 2018) – Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), announced the approval of Credelio® (lotilaner). Credelio is a new monthly oral tick and flea treatment that is easy on dogs, but tough on ticks and fleas. This new tick and flea option for dogs contains the patented active ingredient lotilaner, which targets the nervous system receptors of ticks and fleas, not dogs.¹

Greenfield, Ind. (January, 2018) – Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), received two of the top honors in both food and companion animal innovation from Animal Pharm, a leading industry publication. During the 2017 award cycle, Galliprant (grapiprant tablets) was named Animal Pharm’s Best Companion Animal Product and Clynav took top honors as Best Food Animal Product.

GREENFIELD, IND. (January 25, 2018) – Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), is pleased to announce a new global in-licensing agreement with Ab E Discovery to further develop and bring to market an egg antibody focused on supporting gut health, and thereby the growth and welfare, of poultry.

GREENFIELD, IND. (February 13, 2018) – One of the most discussed – and surprisingly divisive – topics today is agriculture and how our food is raised. GMOs, organic, cage-free: academics and activists alike are looking for the magic recipe to produce enough food for the growing population while safeguarding human health, animal welfare and the environment.

Greenfield (IN), U.S., 20th March 2018 - Elanco Animal Health, together with the COAST Development Group, today announce the publication of a proposal for a practical diagnostic aid, called ‘COAST’ (Canine OsteoArthritis Staging Tool) – A tool expected to improve the diagnosis and monitoring of dogs with osteoarthritis with the potential to guide disease management plans.

Greenfield, Ind. (April 23, 2018) – Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), named Christopher Jensen as senior vice president and chief financial officer (CFO), joining Elanco’s Leadership Team and reporting to Elanco president, Jeffrey Simmons and Josh Smiley, senior vice president of Global Services and CFO at Lilly.